PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
-1.59%
G&A reduction while AVXL shows 1.55% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
14.64%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-14.78%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Operating income decline while AVXL shows 7.38% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-15.16%
Pre-tax income decline while AVXL shows 8.10% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense growth less than half of AVXL's 79.22%. David Dodd would verify if advantage is sustainable.
-15.16%
Net income decline while AVXL shows 8.04% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth below 50% of AVXL's 15.64%. Michael Burry would check for structural issues.
2.78%
Diluted EPS growth below 50% of AVXL's 15.64%. Michael Burry would check for structural issues.
19.07%
Share count reduction below 50% of AVXL's 8.78%. Michael Burry would check for concerns.
19.07%
Diluted share reduction below 50% of AVXL's 8.78%. Michael Burry would check for concerns.